1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Cardiovascular Inflammation – Pipeline Review, H1 2013

Cardiovascular Inflammation – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 75 pages

Cardiovascular Inflammation – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Cardiovascular Inflammation - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cardiovascular Inflammation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cardiovascular Inflammation. Cardiovascular Inflammation - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cardiovascular Inflammation.
- A review of the Cardiovascular Inflammation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cardiovascular Inflammation pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cardiovascular Inflammation.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cardiovascular Inflammation pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Cardiovascular Inflammation - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Cardiovascular Inflammation Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Cardiovascular Inflammation 8
Cardiovascular Inflammation Therapeutics under Development by Companies 10
Cardiovascular Inflammation Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Discovery and Pre-Clinical Stage Products 16
Comparative Analysis 16
Cardiovascular Inflammation Therapeutics - Products under Development by Companies 17
Cardiovascular Inflammation Therapeutics - Products under Investigation by Universities/Institutes 18
Companies Involved in Cardiovascular Inflammation Therapeutics Development 19
Biogen Idec Inc. 19
GlaxoSmithKline plc 20
Teijin Pharma Limited 21
Novartis AG 22
Genfit 23
Pluristem Therapeutics Inc. 24
Priaxon AG 25
t2cure GmbH 26
RNL BIO Co., Ltd. 27
Ampio Pharmaceuticals, Inc. 28
Cardiovascular Inflammation - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
belimumab - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
canakinumab - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
SAVX-1 - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
PLX-PAD - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
t2c-001 - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
abatacept - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
rituximab - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
DMI-4983 - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
venilon - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
Vascostem - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
Autologous Adipose Tissue Derived Mesenchymal Stem Cell - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
AOC3/SSAO Antagonists - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
Coxsackievirus B3 3C Protease Inhibitor - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
triamcinolone - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
Cardiovascular Inflammation Therapeutics - Drug Profile Updates 57
Cardiovascular Inflammation Therapeutics - Discontinued Products 68
Cardiovascular Inflammation Therapeutics - Dormant Products 69
Cardiovascular Inflammation - Product Development Milestones 70
Featured News and Press Releases 70
Aug 17, 2012: Anges Announces Publication Of Long-Term Phase I/II Trial Data Of Collategene In Medical Journal 70
Aug 16, 2012: Pluristem Receives Approval From Indian Ministry Of Health For Use Of PLX Cells In Phase II Trial For Treatment Of Buerger's Disease 70
May 26, 2012: ChemoCentryx Presents Data on CCX168 At 49th European Renal Association-European Dialysis And Transplant Association Congress 71
Jan 25, 2012: Health Canada Approves Roche's RITUXAN To Treat Severe Forms Of Vasculitis 72
Oct 17, 2011: ChemoCentryx Initiates Phase II Clinical Trial For CCX168 In Vasculitis 72
Aug 25, 2011: Pluristem's PLX Cells Receives Orphan Drug Status For Treatment Of Buerger's Disease 73
Mar 24, 2011: AnGes Publishes Results Of Collategene Study In International Angiology 73
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 75
Disclaimer 75



List of Tables

Number of Products Under Development for Cardiovascular Inflammation, H1 2013 8
Products under Development for Cardiovascular Inflammation - Comparative Analysis, H1 2013 9
Number of Products under Development by Companies, H1 2013 11
Number of Products under Investigation by Universities/Institutes, H1 2013 12
Comparative Analysis by Late Stage Development, H1 2013 13
Comparative Analysis by Mid Clinical Stage Development, H1 2013 14
Comparative Analysis by Early Clinical Stage Development, H1 2013 15
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 16
Products under Development by Companies, H1 2013 17
Products under Investigation by Universities/Institutes, H1 2013 18
Biogen Idec Inc., H1 2013 19
GlaxoSmithKline plc, H1 2013 20
Teijin Pharma Limited, H1 2013 21
Novartis AG, H1 2013 22
Genfit, H1 2013 23
Pluristem Therapeutics Inc., H1 2013 24
Priaxon AG, H1 2013 25
t2cure GmbH, H1 2013 26
RNL BIO Co., Ltd., H1 2013 27
Ampio Pharmaceuticals, Inc., H1 2013 28
Assessment by Monotherapy Products, H1 2013 29
Assessment by Stage and Route of Administration, H1 2013 31
Assessment by Stage and Molecule Type, H1 2013 33
Cardiovascular Inflammation Therapeutics - Drug Profile Updates 57
Cardiovascular Inflammation Therapeutics - Discontinued Products 68
Cardiovascular Inflammation Therapeutics - Dormant Products 69



List of Figures

Number of Products under Development for Cardiovascular Inflammation, H1 2013 8
Products under Development for Cardiovascular Inflammation - Comparative Analysis, H1 2013 9
Products under Development by Companies, H1 2013 10
Products under Investigation by Universities/Institutes, H1 2013 12
Late Stage Products, H1 2013 13
Mid Clinical Stage Products, H1 2013 14
Early Clinical Stage Products, H1 2013 15
Discovery and Pre-Clinical Stage Products, H1 2013 16
Assessment by Monotherapy Products, H1 2013 29
Assessment by Route of Administration, H1 2013 30
Assessment by Stage and Route of Administration, H1 2013 31
Assessment by Molecule Type, H1 2013 32
Assessment by Stage and Molecule Type, H1 2013 33

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Global Catheters, Needles, and Cannulas Market Outlook: 2016-2021

Global Catheters, Needles, and Cannulas Market Outlook: 2016-2021

  • $ 6575
  • Industry report
  • December 2016
  • by Meticulous Research

With the continuous development in the medical field due to growing need to curtail increasing healthcare costs, rising focus on patient safety, mounting aging population, and rising prevalence of various ...

Cardiovascular Surgical Devices: Technologies and Global Markets

Cardiovascular Surgical Devices: Technologies and Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Learn about the trends and developments affecting each type of cardiovascular surgical technology - Analyze trends and opportunities in major regions: North America, Europe, Asia ...

Asia-Pacific Ophthalmic Lasers Market Outlook to 2022

Asia-Pacific Ophthalmic Lasers Market Outlook to 2022

  • $ 5995
  • Industry report
  • December 2016
  • by Global Data

Asia-Pacific Ophthalmic Lasers Market Outlook to 2022 Summary GlobalData’s new report, "Asia-Pacific Ophthalmic Lasers Market Outlook to 2022", provides key market data on the Asia-Pacific Ophthalmic ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.